Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 7/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.38 |
| ▸ | ACVR2A | P27037 | 2/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477073 | 0.89 | CSNK1E (0.52) | CSNK1EPDE10AACVR2ATGFBR2 | |
| SCHEMBL477074 | 0.89 | CSNK1E (0.52) | CSNK1EPDE10AACVR2ATGFBR2 | |
| SCHEMBL477183 | 0.87 | CSNK1E (0.59) | CSNK1EDPP4TLR9TLR7TLR8 | |
| SCHEMBL477027 | 0.85 | CSNK1E (0.51) | CSNK1EDPP4 | |
| SCHEMBL477114 | 0.85 | CSNK1E (0.51) | CSNK1EDPP4 | |
| SCHEMBL477072 | 0.82 | CSNK1E (0.69) | CSNK1ERIPK3 | |
| SCHEMBL3121985 | 0.81 | CSNK1E (0.57) | CSNK1EPDE10ARIPK3 | |
| SCHEMBL477145 | 0.79 | CSNK1E (0.67) | CSNK1ERIPK3 | |
| SCHEMBL477007 | 0.76 | CSNK1E (0.55) | CSNK1EPDE10A | |
| SCHEMBL477009 | 0.76 | CSNK1E (0.55) | CSNK1EPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331546-B1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | claimed |
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-12-22 | — | — | US | claimed |
| EP-2331546-B1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-12-22 | — | — | US | disclosed |
| EP-2331546-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | Sanofi-aventis (FR) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010018327-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | NR3C1, CNKSR1, NR3C2 | CSNK1E 2760/4885PDE10A 3179/4885DPP4 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.